Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
27 October 2015

ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs

14 August 2015

Notice of call of the Extraordinary General Shareholders’ meeting

17 August 2015

ORYZON leads an Eurostars project to promote new epigenetic treatments

18 August 2015

Oryzon continues to advance prosecution of its LSD1 patent portfolio worldwide

24 August 2015

ORYZON to Present at the 15ª Annual Biotech in Europe Forum for Global Partnering & Investment in Basel, Switzerland

27 August 2015

ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York, USA

31 August 2015

ORYZON to Present at The Epigenetics Discovery Congress in London

16 September 2015

ORYZON shareholders approve listing to the Spanish Continuous Market

7 September 2015

ORYZON achieves milestone in the clinical development of ORY-1001

2 March 2015

Dr. Carlos Buesa, Oryzon Genomics CEO, to be a Keynote Speaker at the 15th Annual Global Discovery-Summit 2015 in Lisbon, Portugal

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Current page 50
  • Page 51
  • Page 52
  • Page 53
  • Page 54
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel